Since PD-L1 is a predictor biomarker of immunotherapy response in advanced Non-Small-Cell lung cancer (NSCLC) [48], we sought to apply ELEXO to detect PD-L1 in serum EVs isolated from 6 NSCLC samples (Table S1, Fig. 2G), thus confirming the clinical applicability of ELEXO. The gene discussed is CD274; the disease is non-small cell lung carcinoma.